This week, seven top executives from drug manufacturers will testify in a highly anticipated hearing before the Senate Finance Committee. These companies will be questioned regarding rising drug prices, transparency, patent issues, and corporate profits. As drug costs remains a top issue for voters, there is bipartisan momentum for the CREATES Act, which would combat anticompetitive practices to block lower-cost generic drugs from reaching the market.
Keep in mind that the CREATES Act is being seen as a “pay-for” since it is expected to save the government a net $3.9 billion over 10 years if passed. With several critical health care extenders up for reauthorization at the end of the fiscal year, including for Community Health Centers, it’s possible CREATES could be attached to offset some of those costs.
Please see full publication below for more information.
